Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MONOKET vs ISORDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
Angina pectoris (prophylaxis and acute treatment),Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
Isosorbide mononitrate is less than 5% bound to plasma proteins.
~28% bound to albumin.
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
2–4 L/kg, indicating extensive tissue distribution.
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypotension (especially with volume depletion or alcohol),Tolerance with prolonged use (intermittent dosing recommended),Exacerbation of angina upon abrupt withdrawal,Use cautiously in hypertrophic cardiomyopathy
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
Hypersensitivity to nitrates,Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (head trauma, cerebral hemorrhage),Acute circulatory failure (shock, vascular collapse)
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.,For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.,Avoid alcohol as it can increase the risk of hypotension and dizziness.,Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.,Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MONOKET vs ISORDIL, answered by our medical review team.
MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. ISORDIL is a Nitrate Vasodilator that works by Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MONOKET and ISORDIL depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. The standard adult dose of ISORDIL is: Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MONOKET and ISORDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. ISORDIL is classified as Category C. Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.